What is AbbVie's one-year return?

AbbVie's one-year return is 40.9%.

What is the Apogee deal AbbVie entered?

AbbVie acquired Apogee, though the deal value was not detailed in the report.

Is AbbVie stock overvalued?

The report suggests the stock may be overvalued after the recent rally, but it depends on future growth.

AbbVie (ABBV) Stock Valuation After 41% Rally and Apogee Deal

AbbVie (ABBV) stock has rallied 40.9% over the past year, reaching $253.35, amid the Apogee acquisition deal. This analysis examines whether the current price reflects fair value.

June 29, 2026

2 min read

Source: Simply Wall St.

Key Numbers

current price

253.35

one year return

40.9%

five year return

165.3%

AbbVie (ABBV) stock has surged 40.9% over the past year to $253.35, drawing attention to whether the current price reflects the company's fundamentals. The rally coincides with AbbVie's acquisition of Apogee. This analysis aims to assess valuation after these developments.

Recommendation Change

No change in analyst recommendation was reported; the focus is on comparing price to fundamentals.

Analyst Rationale

The report emphasizes comparing current price to fundamentals such as earnings and future growth. With strong 5-year returns of 165.3%, the stock may appear overvalued, but that depends on future growth expectations.

Context

Recent performance: 10.1% over 7 days, 16.4% over 30 days, 10.5% year-to-date. The Apogee deal could enhance AbbVie's product pipeline.

Conclusion

Investors should balance strong historical returns against the possibility that the stock has exceeded fair value. Monitoring fundamentals and future guidance is key.

Frequently Asked Questions

AbbVie (ABBV) current stock price is $253.35.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.